UA95310C2 - Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака - Google Patents
Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения ракаInfo
- Publication number
- UA95310C2 UA95310C2 UAA200903745A UAA200903745A UA95310C2 UA 95310 C2 UA95310 C2 UA 95310C2 UA A200903745 A UAA200903745 A UA A200903745A UA A200903745 A UAA200903745 A UA A200903745A UA 95310 C2 UA95310 C2 UA 95310C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cyclodextrin
- cancer
- treatment
- chkl inhibitor
- composition containing
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Раскрыты композиции, содержащие по меньшей мере один ингибитор Chk1 и по меньшей мере один циклодекстрин. Раскрыты также способы лечения рака или повышения эффективности лечения рака композицией, содержащей по меньшей мере один ингибитор Chk1 и по меньшей мере один циклодекстрин.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85305606P | 2006-10-20 | 2006-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA95310C2 true UA95310C2 (ru) | 2011-07-25 |
Family
ID=39338658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200903745A UA95310C2 (ru) | 2006-10-20 | 2007-10-02 | Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака |
Country Status (22)
Country | Link |
---|---|
US (1) | US8455471B2 (ru) |
EP (1) | EP2063879A2 (ru) |
JP (1) | JP2010506942A (ru) |
KR (2) | KR20110098009A (ru) |
CN (1) | CN101528215B (ru) |
AU (1) | AU2007325576B2 (ru) |
BR (1) | BRPI0717460A2 (ru) |
CA (1) | CA2673483C (ru) |
CO (1) | CO6180503A2 (ru) |
CR (1) | CR10680A (ru) |
EA (1) | EA200900571A1 (ru) |
IL (1) | IL197869A (ru) |
MA (1) | MA30872B1 (ru) |
MX (1) | MX2009004214A (ru) |
MY (1) | MY150649A (ru) |
NO (1) | NO20091544L (ru) |
NZ (1) | NZ575394A (ru) |
SV (1) | SV2009003227A (ru) |
TN (1) | TN2009000146A1 (ru) |
UA (1) | UA95310C2 (ru) |
WO (1) | WO2008067027A2 (ru) |
ZA (1) | ZA200902670B (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
WO2010138920A1 (en) | 2009-05-29 | 2010-12-02 | Cydex Pharmaceuticals, Inc. | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
WO2013040286A2 (en) * | 2011-09-18 | 2013-03-21 | Euro-Celtique S.A. | Pharmaceutical compositions |
BR112014007694B1 (pt) | 2011-10-03 | 2022-09-27 | Respivert Limited | Compostos de 1-(3-(tert-butil)-1-(p-tolil)-1h-pirazol-5-il)-3-(4-((2-(fenilamino) pirimidin-4-il)óxi) naftalen-1-il)ureia, seus usos, composição e formulação farmacêutica compreendendo os mesmos |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
EP4299121A2 (en) | 2012-04-13 | 2024-01-03 | L&F Research LLC | Method of using cyclodextrin |
CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
EA034927B1 (ru) | 2014-02-14 | 2020-04-07 | Респайверт Лимитед | Ароматические гетероциклические соединения как противовоспалительные соединения |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US9890564B2 (en) | 2014-10-28 | 2018-02-13 | Sargent Manufacturing Company | Interconnected lock with direct drive for adjustable deadbolt to latchbolt spacing |
JP2017155023A (ja) * | 2016-03-04 | 2017-09-07 | ジェイファーマ株式会社 | Lat1阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤 |
US20200000840A1 (en) * | 2016-03-20 | 2020-01-02 | Asdera Llc | Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders |
WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
EP3687549A4 (en) | 2017-09-28 | 2021-07-14 | Asdera LLC | USE OF CYCLODEXTRIN IN DISEASES AND DISORDERS WITH PHOSPHOLIPID FAILURE REGULATION |
CN109078005B (zh) * | 2018-08-07 | 2021-11-26 | 江苏领航生物科技有限公司 | 一种白消安组合物及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
HU193933B (en) | 1984-06-08 | 1987-12-28 | Nitrokemia Ipartelepek | Herbicide or plant growth stimulating agent comprising beta-cyclodextrin complex of benzolsulphonylurea derivative and process for preparing the active substances |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9001987D0 (en) | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
EP1067942A1 (en) * | 1998-02-23 | 2001-01-17 | Cyclops, EHF. | High-energy cyclodextrin complexes |
JP2004504360A (ja) * | 2000-07-24 | 2004-02-12 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 1−(5−tert−ブチル−2−P−トリル−2H−ピラゾール−3−イル)−3−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−ウレアの改良された経口製剤 |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
CA2454913A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin |
SE0201658D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
RU2006112548A (ru) * | 2003-09-17 | 2007-10-27 | Айкос Корпорейшн (Us) | Применение ингибиторов снк1 для регуляции пролиферации клеток |
KR20050039573A (ko) * | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
SI1869020T1 (sl) * | 2005-03-29 | 2011-02-28 | Icos Corp | Derivati heteroaril uree, ki so uporabni za inhibicijo chk1 |
CN1813739A (zh) | 2005-11-25 | 2006-08-09 | 王颖 | 一种注射用盐酸纳美芬冻干粉针制剂 |
-
2007
- 2007-10-02 WO PCT/US2007/080150 patent/WO2008067027A2/en active Application Filing
- 2007-10-02 CN CN2007800390301A patent/CN101528215B/zh not_active Expired - Fee Related
- 2007-10-02 KR KR1020117017995A patent/KR20110098009A/ko not_active Application Discontinuation
- 2007-10-02 KR KR1020097007975A patent/KR20090065537A/ko not_active Application Discontinuation
- 2007-10-02 MX MX2009004214A patent/MX2009004214A/es active IP Right Grant
- 2007-10-02 EP EP07871106A patent/EP2063879A2/en not_active Withdrawn
- 2007-10-02 US US12/442,529 patent/US8455471B2/en not_active Expired - Fee Related
- 2007-10-02 NZ NZ575394A patent/NZ575394A/en not_active IP Right Cessation
- 2007-10-02 AU AU2007325576A patent/AU2007325576B2/en not_active Ceased
- 2007-10-02 EA EA200900571A patent/EA200900571A1/ru unknown
- 2007-10-02 MY MYPI20091558 patent/MY150649A/en unknown
- 2007-10-02 CA CA2673483A patent/CA2673483C/en not_active Expired - Fee Related
- 2007-10-02 JP JP2009533425A patent/JP2010506942A/ja active Pending
- 2007-10-02 UA UAA200903745A patent/UA95310C2/ru unknown
- 2007-10-02 BR BRPI0717460-8A2A patent/BRPI0717460A2/pt not_active IP Right Cessation
-
2009
- 2009-03-20 CR CR10680A patent/CR10680A/es unknown
- 2009-03-26 IL IL197869A patent/IL197869A/en not_active IP Right Cessation
- 2009-04-17 TN TNP2009000146A patent/TN2009000146A1/fr unknown
- 2009-04-17 ZA ZA200902670A patent/ZA200902670B/xx unknown
- 2009-04-17 CO CO09039148A patent/CO6180503A2/es not_active Application Discontinuation
- 2009-04-20 NO NO20091544A patent/NO20091544L/no not_active Application Discontinuation
- 2009-04-20 SV SV2009003227A patent/SV2009003227A/es unknown
- 2009-05-07 MA MA31850A patent/MA30872B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20100022512A1 (en) | 2010-01-28 |
CA2673483C (en) | 2014-04-08 |
TN2009000146A1 (en) | 2010-10-18 |
IL197869A (en) | 2013-11-28 |
US8455471B2 (en) | 2013-06-04 |
AU2007325576A1 (en) | 2008-06-05 |
MA30872B1 (fr) | 2009-11-02 |
KR20110098009A (ko) | 2011-08-31 |
NO20091544L (no) | 2009-06-10 |
CA2673483A1 (en) | 2008-06-05 |
BRPI0717460A2 (pt) | 2013-12-24 |
EA200900571A1 (ru) | 2009-12-30 |
CN101528215B (zh) | 2011-10-19 |
MY150649A (en) | 2014-02-14 |
NZ575394A (en) | 2012-01-12 |
MX2009004214A (es) | 2009-05-11 |
CN101528215A (zh) | 2009-09-09 |
SV2009003227A (es) | 2010-02-04 |
WO2008067027A2 (en) | 2008-06-05 |
AU2007325576B2 (en) | 2013-01-10 |
KR20090065537A (ko) | 2009-06-22 |
EP2063879A2 (en) | 2009-06-03 |
WO2008067027A3 (en) | 2009-04-16 |
CR10680A (es) | 2009-10-13 |
IL197869A0 (en) | 2009-12-24 |
ZA200902670B (en) | 2010-06-30 |
JP2010506942A (ja) | 2010-03-04 |
CO6180503A2 (es) | 2010-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA95310C2 (ru) | Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака | |
IL257681A (en) | Methods and compositions for the treatment of cancer | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
WO2007053573A3 (en) | Treatment of cancer with sorafenib | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
TN2009000255A1 (en) | Quinazolines for pdk1 inhibition | |
MX2009009761A (es) | Composiciones y estuches para tratamiento de la influenza. | |
MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
SG10201811480WA (en) | Therapeutic compounds and compositions | |
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
WO2008030883A3 (en) | Treatment of cancer | |
SG164368A1 (en) | Treatment of cancer | |
WO2007059154A3 (en) | Treatment of cancers with acquired resistance to kit inhibitors | |
MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
ZA200708575B (en) | Methods and compositions for treating or preventing cancer | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
PL2529626T3 (pl) | Kompozycje i sposoby leczenia lub zapobiegania nowotworowi okrężnicy | |
WO2007081751A9 (en) | Compositions and methods for the treatment of cancer | |
WO2010059004A3 (ko) | 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제 | |
EP2331093A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATMENT PREVENTING DISEASES | |
EP2049151A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
GB2466912A (en) | Compositions and methods for treating lysosomal disorders | |
MX2010003365A (es) | Derivados de tiazol para el tratamiento de cancer. | |
HK1162502A1 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3 | |
BRPI0603772A (pt) | composições para a inibição ou redução de inflamação da pele |